Reta vs Tirzepatide: Mechanism & Research Comparison
Last updated: 9 June 2026
An objective research comparison. The reta supplied by DXB Peptides is for in vitro laboratory research only — not for human consumption.
If semaglutide represented the first generation of nutrient-hormone weight-management compounds, reta and tirzepatide represent the multi-receptor generation that followed. Tirzepatide is the approved dual agonist that is currently best-in-class; reta is the investigational triple agonist positioned as a potential next step. This page compares their mechanisms, the trial data published to date, and their development status, for research and informational context only.
At a glance
| Reta | Tirzepatide | |
|---|---|---|
| Receptors targeted | Three: GLP-1, GIP, and glucagon | Two: GIP and GLP-1 |
| Class | Triple agonist (investigational) | Dual agonist (approved) |
| Development stage | Phase 3 — investigational | Approved (Mounjaro / Zepbound) |
| Reported trial weight reduction | ~24% at 48 weeks (Phase 2) | ~21–23% (SURMOUNT) |
| Approved for human use? | No | Yes |
The mechanistic difference
Both compounds build on the same foundation: each activates the GIP and GLP-1 receptors, the incretin pathways involved in appetite regulation. The difference is one receptor. Tirzepatide stops at two — it is a dual GIP/GLP-1 agonist. Reta adds a third target, the glucagon receptor.
That glucagon-receptor activation is the defining distinction between a dual and a triple agonist. Beyond the appetite effects shared via GIP and GLP-1, glucagon signalling is involved in hepatic glucose regulation and energy expenditure. The research rationale for the triple-agonist approach is that engaging this third pathway could broaden the metabolic effect beyond what dual agonism achieves.
What the trials reported
Tirzepatide’s pivotal SURMOUNT program reported mean weight reductions of roughly 21% at 72 weeks (15 mg dose), with three-year data reaching approximately 23%. It also has direct head-to-head evidence: in the SURMOUNT-5 trial, tirzepatide outperformed semaglutide (about 20% versus 14%). Reta, in its Phase 2 obesity trial (NEJM, 2023), reported a mean reduction of roughly 24% at 48 weeks at the highest dose, with more recent Phase 3 reporting indicating even larger figures.
An important caveat: unlike the tirzepatide-versus-semaglutide comparison, there is no published head-to-head trial of reta against tirzepatide. Reta’s apparent edge comes from separate trials with different populations and timeframes. It is a reasonable research signal, but it is not the same as a direct comparison — only a head-to-head trial could establish a true difference.
Development status
Tirzepatide is approved and available — as Mounjaro for type 2 diabetes (2022) and Zepbound for obesity (2023) — and is backed by a large, ongoing trial program. Reta remains investigational: it is in Phase 3 and is not approved for human use in any jurisdiction, with commercial availability not expected before 2027 at the earliest. In short, tirzepatide is the established, validated option today; reta is the research frontier.
Both share the class-typical gastrointestinal side-effect profile reported in their trials, dominated by nausea during dose escalation.
Learn more
See also our reta vs semaglutide comparison, and our full reta research overview. DXB Peptides supplies research-grade reta for in vitro laboratory use — HPLC-tested to ≥99% purity with a batch-specific COA, cold-chain handled and delivered across the UAE.
Frequently asked questions
What is the difference between reta and tirzepatide? The number of receptors. Tirzepatide is a dual GIP/GLP-1 agonist; reta is a triple agonist that adds the glucagon receptor.
Is reta more effective than tirzepatide? In their separate trials, reta reported larger reductions, but there is no head-to-head trial between the two — so a definitive comparison cannot be made from current data.
Is reta approved? No. It is investigational and in Phase 3. Tirzepatide is approved (Mounjaro / Zepbound) and available now.
Are they the same class? They are related multi-agonists built on the incretin pathways, but tirzepatide is a dual agonist and reta is a triple agonist — a distinct, newer category.
Important note
This page is an objective comparison for research and informational purposes and is not medical advice. The reta supplied by DXB Peptides is a research compound for in vitro laboratory use only — it is not approved for human use and is not for human consumption or in vivo administration.
Explore the full catalogue: Research peptides UAE